WARSAW — Vein Institute & Medical Spa, Inc. in Warsaw is among a select group of practices nationwide chosen to participate in the early release of Xeomin, the latest injectable wrinkle treatment. Xeomin will not be available in most of the country until April, 2012.
“I am so excited to start working with this new product,” Jennifer Kauffman, Board Certified Nurse Practitioner, said. “Botox has had the monopoly on the market for the last 12 years. This new option will only benefit the patient.”
Like Botox® Cosmetic and Dysport®, Xeomin is FDA-approved for the temporary correction of moderate to severe frown lines between the eye brows. Manufactured by Merz Aesthetics, Xeomin has been used in Europe since 2008. The U.S. is the 20th country to approve its use. Botulinum type a products are typically recommended for cosmetic treatment of: forehead lines, frown lines and crow’s feet.
This drug acts similarly to Botox and Dysport. As Botox and Dysport currently are the “Coke-Pepsi” equivalents in wrinkle fighters, Xeomin will add to the “taste test” for the elimination of unwanted facial wrinkles. It is hoped that having three agents made by different companies will help to bring the cost down of the products.
Xeomin is a simple, painless, in-office procedure. The entire procedure typically takes less than 15 minutes and involves only minimal discomfort. Patients can return to work or daily activities immediately after. Full results will be visible between three to seven days after injection, and typically last between three to six months. Like Botox and Dysport, results can actually improve over time with repeated injections, as the muscle becomes conditioned to being relaxed.
For more information, call Vein Institute & Medical Spa, Inc. at 574-267-1900 or visit www.veinmedicalspa.com.